© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
December 23, 2019
The recent development of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, as well as alpelisib (Piqray), a phosphoinositide 3-kinase (PI3K) inhibitor, has changed the way patients with HR-positive MBC are treated.